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Background: Pancreatic ductal adenocarcinoma (PDAC) is still a lethal malignancy. Long noncoding RNAs
(lncRNAs) have been shown to play a critical role in cancer development and progression. Here we identified
overexpression of the lncRNA AFAP1-AS1 in PDAC patients and evaluated its prognostic and functional relevance.
Methods: The global lncRNA expression profile in PDAC was measured by lncRNA microarray. Expression of
AFAP1-AS1 was evaluated by reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) in 90 PDAC
tissue samples and adjacent normal tissues. The impact of AFAP1-AS1 expression on cell proliferation, migration,
and invasion were evaluated in vitro using knockdown and ectopic expression strategies.
Results: Microarray analysis revealed that up-regulation of AFAP1-AS1 expression in PDAC tissues compared with
normal adjacent tissues, which was confirmed by RT-qPCR in 69/90 cases (76.7%). Its overexpression was associated
with lymph node metastasis, perineural invasion, and poor survival. When using AFAP1-AS1 as a prognostic marker, the
areas under ROC curves were 0.8669 and 0.9370 for predicting tumor progression within 6 months and 1 year,
respectively. In vitro functional experiments involving knockdown of AFAP1-AS1 resulted in attenuated PDAC cell
proliferation, migration, and invasion. Ectopic expression of AFAP1-AS1 promoted cell proliferation, migration,
and invasion.
Conclusions: AFAP1-AS1 is a potential novel prognostic marker to predict the clinical outcome of PDAC patients
after surgery and may be a rational target for therapy.
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Pancreatic ductal adenocarcinoma (PDAC) remains one
of the most aggressive human cancers [1]. Despite sub-
stantial efforts, PDAC is associated with a short survival
that has been declining steadily since the early 1990s [2].
PDAC is characterized by a highly malignant phenotype
that is associated with early metastasis and resistance to
chemotherapy and radiation therapy [3]. There is an ur-
gent need for further understanding of the mechanism* Correspondence: chent_sysu@163.com; chent_sysu@163.com
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medium, provided the original work is properly
(http://creativecommons.org/publicdomain/zeroof PDAC development and new innovative therapeutic
approaches. Identifying the underlying molecular mech-
anisms of invasion and metastasis in PDAC will be es-
sential for the identification of effective drug targets.
In recent years, it has become increasingly apparent
that the noncoding portion of the genome is of crucial
functional importance in both normal physiology and
diseases [4]. Long noncoding RNAs (lncRNAs), which
are defined as those longer than ~200 nucleotides but
lacking protein coding capacity [3], have recently been
shown to play a key role in regulating vital cellular func-
tions including cancer progression [5]. To date, thou-
sands of lncRNAs have been discovered through
chromatin signature analysis and large-scale sequencing,
and functional studies have shown that many of themdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any
credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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nificance [6]. Importantly, many lncRNAs have been
identified as being cancer-specific [5,7]. For example, ab-
errant expression of lncRNA HOTAIR was associated
with various cancers such as breast, hepatocellular, gas-
tric, colorectal, and pancreatic, and its expression was
associated with survival and prognosis of cancer patients
[8]. MALAT1 was discovered as a prognostic marker for
lung cancer metastasis but also been linked to several other
human malignancies [9]. Other examples include HULC in
hepatocellular carcinoma [10] and PCGEM1 in prostate
cancer [11,12]. In pancreatic, a number of lncRNAs were
found to exhibit pro-oncogenic or tumor-suppressive ac-
tivities, such as ENST00000480739 [13], LOC285194 [13],
HULC [14], HOTAIR [15], and MALAT1 [16], suggesting
an important of lncRNAs in progression of pancreatic
cancer. Therefore, identification of lncRNAs involved in
PDAC progression might help yield novel prognostic bio-
markers or therapeutic targets.
In this study, we observed that a lncRNA, AFAP1-AS1,
was substantially overexpressed in PDAC tissues. Knock-
down of AFAP1-AS1 could inhibit cell proliferation,
migration, and invasion of PDAC cells. Moreover,
AFAP1-AS1 expression correlated with lymph node me-
tastasis, perineural invasion, and poor survival in PDAC
patients. Our results suggest that AFAP1-SA1 may repre-
sent a novel indicator of poor prognosis and a potential
therapeutic target in PDAC.
Methods
Cell culture
The human pancreatic cancer cell lines Panc1 (CRL-
1469™), MIAPaCa-2(CRL-1420™), Capan2(HTB-80™),
SW1990(CRL-2172™), and BXPC-3 (CRL-1687™), and
the human pancreatic ductal epithelial cells line HPDE6
were purchased from the American Type Culture Col-
lection and grown in complete growth medium as rec-
ommended by the supplier with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin. All cells were cul-
tured in a humidified 5% CO2 incubator at 37°C.
RNA Isolation, quantitative real-time reverse-transcription
polymerase chain reaction (PCR), and microarrays
Quantitative real-time PCR (RT-qPCR) was performed for
AFAP1-AS1 and the epithelial–mesenchymal transition
(EMT) markers E-cadherin, N-cadherin, Vimentin, Snai1,
and Slug. β-Actin was used as an internal control. RNA
was extracted from frozen pancreatic cancer tissues and
their corresponding non-neoplastic tissues and pancreatic
cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA,
USA). The total RNA was then converted to cDNA by
reverse-transcription using oligodT primers and Super-
Script II reverse transcriptase (Invitrogen). For real-time
quantitative PCR, three replicates of each sample wereamplified and analyzed using a Roche Light-Cycler (Roche,
Basel, Switzerland). The 20 μl reaction mixtures contained
SYBR Green reaction mix (Qiagen Sciences) and 0.5 mM
of primer. Relative gene expression was determined using
the comparative delta-delta CT method (2-ΔΔCt). The
primer sequences for PCR were provided in the supple-
mentary materials (Additional file 1).
Transcriptomic analysis was performed using Arrays-
tar human lncRNA microarrays, V3 (Agilent, USA),
which target 27958 Entrez protein-coding genes and
7419 lncRNAs. Total RNA was extracted and mRNA
was purified using the mRNA-ONLYTM Eukaryotic
mRNA Isolation Kit (Epicentre). Total RNA was frag-
mented, labeled (One-Color, Cy3, Agilent), purified, and
hybridized with probes in Hybridization Chamber gasket
slides (Agilent). The slides were then washed and
scanned with an Agilent Microarray Scanner. The raw
data were extracted with Agilent Feature Extraction
software (Agilent Technology). This software uses the
robust multi-array average algorithm to adjust the back-
ground signals. Normalized data were obtained after
performing the quantile method of intra-microarray
normalization and the median method of baseline
transformation between the microarrays. Differentially
expressed genes with a raw expression level of >400 in
more than 4 out of the 12 samples used for profiling
were extracted and ordered by p-value. Genes with the
highest top 10 p-values were selected for validation.
The microarray platform and data were submitted to
the Gene Expression Omnibus public database at the
National Center for Biotechnology Information (acces-
sion number: GSE61166, http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE61166).Immunoblotting
Immunoblotting was performed as described previously
[17]. Briefly, cells were washed in phosphate-buffered sa-
line (PBS) and lysed with RIPA buffer (Invitrogen,
Carlsbad, CA) plus protease inhibitor cocktail (Roche,
Mannheim, Germany). For equal protein loading, a
bicinchoninic acid protein assay kit (Pierce) was used
to calculate protein concentration in each sample.
Equivalent amounts of proteins were subjected to
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis, transferred to a polyvinylidene fluoride mem-
brane, blocked in 5% fat-free milk for 2 hours at room
temperature, and detected with appropriate primary
antibodies. The following antibodies were used for
analysis: anti-E-cadherin (1:1000; BD Biosciences, CA,
USA), anti-N-cadherin (1:1000; BD Biosciences), anti-
Vimentin (1:1000; BD Biosciences), anti-slug (1:1000;
Abcam), anti-snail (1:1000, Abcam), and anti-β-actin
(Sigma). β-Actin was used for loading controls.
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bodies (Cell Signaling Technology), and an ECL
chemiluminescence kit (Pierce) were used to detect
bound antibody.
AFAP1-AS1 knockdown
Vector construction and virus infection
For lentivirus-mediated suppression of human AFAP1-AS1,
the following shRNA and scrambled control shRNA were
inserted into the pMKO.1-puro vector: #1, forward, 5′-C
CGGAGCGGTCTCAGCCGAATGACTCTCGAGAGTC
ATTCGGCTGAGACCGCTTTTTTG-3′ and reverse, 5′-
AATTCAAAAAAGCGGTCTCAGCCGAATGACTCTCG
AGAGTCATTCGGCTGAGACCGCT-3′; #2, forward, 5′-
CCGGAACACCAATCCCAAGAGGTGACTCGAGTCAC
CTCTTGGGATTGGTGTTTTTTTG-3′ and reverse, 5′-
AATTCAAAAAAACACCAATCCCAAGAGGTGACTCG
AGTCACCTCTTGGGATTGGTGTT-3′; scrambled con-




For ectopic expression of AFAP1-AS1, The full-length
AFAP1-AS1 cDNA was generated by reverse transcriptase-
polymerase chain reaction (RT-PCR) using total RNA from
SW1990 pancreatic cancer cell line. The AFAP1-AS1 cDNA
with the wild-type sequence was inserted into the EcoRI
site of the pcDNA3.1(+) expression vector (Invitrogen) to
obtain the AFAP1-AS1wt/pcDNA3.1(+) construct. Lenti-
virus packaging, cell infection and selection of puromycin-
resistant cells was performed as previously described [17].
Cell growth and cell cycle assays
Cell proliferation analysis 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) substrate (Sigma-Al-
drich) was used to assay cell proliferation according to the
manufacturer’s instructions. Briefly, a total of 3 × 103 cells
were seeded into 96-well dishes and allowed to adhere
overnight. The growth curves of cells, covering a total of 3
days of culturing, were determined through measuring ab-
sorbance at 570 nm. After transfection, 5 × 104 SW1990,
MIAPaCa-2 cells, or PANC-1 cells were collected and
washed three times with PBS. After RNase digestion and PI
dyeing, the cells were subjected to FACS analysis.
Migration and invasion assays
The cell migration assay was performed using BD Trans-
well chambers. Cell invasion assays were performed with
chambers uniformly covered with Matrigel (BD Biosci-
ences) diluted with Dulbecco’s modified Eagle’s medium
(DMEM) to a certain percentage and incubated at 37°C for
30 minutes. Cells (1 × 106) were suspended in 200 μl
serum-free DMEM medium and seeded into the upper
chamber of each insert. Then, 600 μl of DMEM containing10% FBS was added to a 24-well plate. After incubation at
37°C for 12 h, the cells that migrated were fixed and stained
for 20 min in a dye solution containing 0.4% crystal violet
and 20% methanol. The cells in the upper layer of the
membrane were removed and the cells in the lower layer
were washed off with 33% acetic acid (500 μl per cham-
ber). The migrated cells was quantified by measuring
the absorbance of eluent at 570 nm. The relative migra-
tion fold change of the experimental group was calcu-
lated by normalizing to that of the control group.
Patient samples
All samples were obtained from patients when undergo-
ing resection of the pancreas at Sun Yat-Sen Memorial
Hospital between 2009 and 2014. Informed consent was
obtained from the patients before sample collection. All
patients had a clear histological diagnosis. Patients’ spec-
imens and the related clinicopathological data, including
complete follow-up, were obtained from the Institute of
Pathology and from the Department of Pancreaticobili-
ary, Sun Yat-Sen Memorial Hospital. All patients in this
study met the following criteria: 1) PDAC diagnosis
was verified by pathological examination; 2) paraffin-
embedded tissues were well stored and qualified for
serial section; 3) the corresponding tumor tissues and
the paired non-tumor tissues were stored in liquid ni-
trogen immediately following surgical removal; 4) no
anticancer treatments given before biopsy collection;
and 5) availability of exhaustive clinicopathologic and
follow-up data.
Tumorigenicity assays in nude mice
All experiments involving animals were conducted accord-
ing to the institutional guidelines of Guangdong Province
and were approved by the institutional guidelines of
Guangdong Province and by the Use Committee for Ani-
mal Care. BALB/c nude mice (5 weeks old) were randomly
separated into the shControl group or the shAFAP1-AS1
group (5 mice per group). SW1990 cells (3 × 106 cells/
mouse) stably transfected with shAFAP1-AS1 or control
shRNA were injected subcutaneously into the right axilla of
each mouse. Tumor volume was calculated using the fol-
lowing formula: volume = (L × W2)/2, where L and W are
the longest and shortest diameters, respectively. The mice
were sacrificed two weeks after injection.
Statistical analysis
Statistical analyses were performed using SPSS Statistics
17.0 (SPSS lnc®). The chi-square test (X2 test), Fisher’s
exact test for nonparametric variables, and Student’s t
test for parametric variables (two-tailed) were used. Dif-
ferences in patient survival were assessed using the
Kaplan–Meier method and analyzed using the log-rank
test in univariate analysis. All tests were two tailed, and
Ye et al. Journal of Translational Medicine  (2015) 13:137 Page 4 of 11results with P = 0.05 were considered statistically
significant.
Results
AFAP1-AS1 is aberrantly overexpressed in human PDAC
cell lines and cancerous tissues
As a first attempt to identify differentially expressed long
noncoding RNAs (lncRNAs) in two subtypes of PDAC
tissues (PDAC patients with diabetes versus PDAC pa-
tients without diabetes), we conducted microarrayFigure 1 AFAP1-AS1 expression in clinical pancreatic ductal adenocarcinom
50 up-regulated long noncoding RNAs in tissue from eight cases of pancre
cases of chronic pancreatitis (CP). Group 1 indicates the most up-regulated
indicated the most up-regulated lncRNAs in PDAC tissues from patients wi
were determined via RT-qPCR, and β-actin was used as internal control. Data ar
P < 0.01, Student’s t-test. (c) AFAP1-AS1 expression levels in 90 paired PDAC tissu
The relative AFAP1-AS1 mRNA level was normalized to β-actin.analysis utilizing a microarray targeting 7419 LncRNAs
using eight cases of PDAC tissues and four cases of
chronic pancreatitis tissues (CP) (accession number:
GSE61166). All of the differentially expressed (> or <2
fold change) lncRNAs were listed in Additional file 2.
We noticed that the long noncoding RNA AFAP1-AS1 is
one of the most up-regulated lncRNAs in both subtypes
of PDAC tissues (Figure 1a), suggesting a potentially im-
portant role for AFAP1-AS1 in PDAC development.
Therefore, we next examined the expression of AFAP1-a specimens and cancer cell lines. (a) Heat map representing the top
atic ductal adenocarcinoma (PDAC) compared with tissue from four
lncRNAs in PDAC tissues from patients with diabetes, and group 2
thout diabetes. (b) The AFAP1-AS1 expression levels in PDAC cell lines
e represented as the mean ± s.d. from three independent experiments. ***:
es and their adjacent noncancerous tissues were examined via RT-qPCR.
Table 1 Correlation of AFAP1-AS1 expression and
clinicopathological characteristics





Age <60 25 20 0.292
≥60 20 25
Sex Male 29 28 0.827
Female 16 17
Differentiation Well 15 18 0.598
Moderate 17 18
Poor 13 9
UICC stage pI 13 11 0.634
pII 32 34
T stage T1 6 9 0.355
T2 18 13
T3 21 13
N stage N0 10 27 0.001
N1 35 18
Perineural invasion Negative 18 29 0.020
Positive 27 16
*Pearson Chi-Square test.
Figure 2 High AFAP1-AS1 expression predicts poor prognosis in PDAC patients with surgical resection. a) and b) Patients were equally divided into
two groups based on AFAP1-AS1 mRNA levels. The log-rank test (2-sided) was used to compare differences between groups. The Kaplan–Meier curves
show analyses of overall survival and progression-free survival. (c) ROC curve analysis was conducted to investigate the value of AFAP1-AS1 in predicting
tumor progression (recurrence and/or metastasis) within 6 months or 1 year after surgical resection.
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pression level of AFAP1-AS1 in each PDAC cell line was
dramatically up-regulated compared with the HPDE6 cell
line (human pancreatic ductal epithelium cell; Figure 1b).
Finally, we sought to identify whether AFAP1-AS1 was up-
regulated in PDAC cell lines and in a large sample size of
PDAC tissues. As shown in Figure 1c, we discovered that
AFAP1-AS1 was widely upregulated in PDAC tissues com-
pared their paired adjacent non-tumor tissues.
High AFAP1-AS1 expression predicts poor prognosis in
PDAC patients with surgical resection
We next asked whether the expression of AFAP1-AS1 cor-
related with the clinical outcome in patients with PDAC.
As shown in Figure 1c, 90 cases of PDAC patients re-
ceived surgical resection were divided into two groups
based on APAF1-AS1 expression with 45 patients in each
group. Log-rank analysis indicated that the overall survival
and progression-free survival was significantly worse in
patients with higher AFAP1-AS1 expression in their tumor
tissues (Figure 2a, b). Statistical analysis also revealed that
AFAP1-AS1 overexpression correlated with lymph node
metastasis and perineural invasion (Table 1). No statistical
correlation with gender, age, tumor stage and tumor grade
was observed. To further determine whether and how
AFAP1-AS1 can serve as a biomarker to predict tumor
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gery, we constructed a ROC (receiver operating character-
istic) curve analysis (Figure 2c). For predicting progression
within 1 year, the area under the ROC curve was 0.8669 (p
< 0.0001) with an optimal cutoff point of 8.797 (tumor/
para-tumor; sensitivity = 69.81%, specificity = 94.59%) and
for predicting progression within in 6 months, the area
under the ROC curve was 0.9370 (p < 0.0001) with an op-
timal cutoff point of 8.797 (tumor/para-tumor; sensitivity
= 83.33%, specificity = 91.67%). These findings suggest
that AFAP1-AS1 has potential diagnostic value in predict-
ing early recurrence of PDAC.
Inhibition of AFAP1-AS1 in PDAC cells leads to reduced
proliferation
To further examine whether AFAP1-AS1 has a causal
role in PDAC progression, in vitro functional studies
were conducted. We knocked down AFAP1-AS1 expres-
sion in MIAPaca-2 and SW1990 cells via stable transfec-
tion, and the efficiency of knockdown of the two
shRNAs was evaluated (Figure 3a), the most effective
shRNA #2 was chose for the following study. AFAP1-
AS1 depletion resulted in decreased tumor cellFigure 3 AFAP1-AS1 knockdown attenuates PDAC cell proliferation. (a) AFA
AFAP1-AS1 knockdown on cancer cell line proliferation was determined by
was measured by flow cytometry. Data are represented as the mean ± s.d.
no homology to any known mammalian genes as a negative control. ***: Pproliferation both in PDAC cell line MIAPaca-2 and
SW1990, as determined by MTT assay (Figure 3b, c).
We also performed cell cycle assays after shRNA trans-
fection using flow cytometry (Figure 3d, e). Results
showed that suppression of AFAP1-AS1 significantly in-
duced G2/M phase arrest. Taken together, these findings
suggest that the AFAP1-AS1 modulates cell proliferation
partly through regulating cell cycle.
AFAP1-AS1 regulates cell migration and invasion
Enhanced cell migration and invasion abilities are key
features associated with cancer metastasis. We therefore
examined whether AFAP1-AS1 knockdown affects these
functions in PDAC cells. As shown in Figure 4a and b,
AFAP1-AS1 knockdown significantly decreased cell mo-
tility. Similarly, a matrigel invasion assay showed that
AFAP1-AS1 knockdown significantly inhibited invasive-
ness in MIAPaca-2 and SW1990 cells (Figure 4c, d). Since
epithelial–mesenchymal transition (EMT) is closely re-
lated with the cell motility and invasiveness, we next
examined whether the knockdown of AFAP1-AS1 affects
the expression of EMT-related genes. Both PCR (Figure 4e
and f) and Western blot analyses (Figure 4g) showed thatP1-AS1 expression level was confirmed by RT-qPCR. (b-c) The effect of
MTT assays. (d-e) The effect of AFAP1-AS1 knockdown on the cell cycle
from three independent experiments; shControl denotes shRNA having
< 0.01, Student’s t-test.
Figure 4 (See legend on next page.)
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Figure 4 AFAP1-AS1 knockdown inhibits migration and invasion of PDAC cells. (a) Representative images of transwell assay after AFAP1-AS1
knockdown in PDAC cell line MIAPaCa-2 and SW1990. (b) Analysis of OD (570 nm) absorbance of crystal violet-stained cells in transwell assay. (c)
Representative images of Matrigel invasion assay after AFAP1-AS1 knockdown in PDAC cell line MIAPaCa-2 and SW1990. (d) Analysis of OD (570
nm) absorbance of crystal violet-stained cells in Matrigel invasion assay. (e-f) Relative mRNA expression levels of EMT-related genes (normalized to
β-actin) in PDAC cells after AFAP1-AS1 knockdown were determined by RT-qPCR. (g) Western blot analysis of E-cadherin, N-cadherin, and
Vimentin. Data are represented as the mean ± s.d. from three independent experiments, shControl denotes shRNA having no homology to
any known mammalian genes as a negative control. ***: P < 0.01, Student’s t-test.
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with upregulation of epithelial marker E-cadherin and
downregulation of mesenchymal markers.
Ectopic expression of AFAP1-AS1 promoted proliferation,
migration, and invasion of pancreatic cancer cell
To further evaluate the oncogenic role of AFAP1-AS1 in
PDAC, ectopic expression of AFAP1-AS1 was carried out
in PANC-1 cells which have the lowest AFAP1-AS1 level
among the five pancreatic cancer cells. Overexpression of
AFAP1-AS1 was confirmed by qRT-PCR (Figure 5a). As
expected, AFAP1-AS1 overexpression resulted in in-
creased tumor cell proliferation (Figure 5b). In addition,
migration assay and invasion assay were also performed
(Figure 5c), and PANC-1 cells showed significant en-
hanced migration and invasion ability after AFAP1-AS1
overexpression (Figure 5d). Both PCR (Figure 5e) and
Western blot analyses (Figure 5f) demonstrated that intro-
duction of AFAP1-AS1 in PANC-1 cells was associated
with down of epithelial marker E-cadherin and upregula-
tion of mesenchymal markers.
Inhibition of AFAP1-AS1 impaired pancreatic cancer cell
tumorigenicity in vivo
To evaluate the effect of AFAP1-AS1 on the efficiency of
xenograft formation of pancreatic cancer cells, we ana-
lyzed the in vivo tumorigenicity of SW1990 cells in nude
mice following the shRNA-mediated knockdown of
AFAP1-AS1. As expected, both tumor volume (Figure 6a,
b) and tumor weight (Figure 6c) were significant decreased
with pancreatic cancer cells when AFAP1-AS1 expression
was inhibited.
Discussion
Although thousands of lncRNAs have recently been iden-
tified, investigation of their respective roles in modulating
gene expression is relatively incomplete. Functional stud-
ies have indicated that some lncRNAs are involved in
human cancer tumorigenesis, progression, and adjuvant
therapy resistance, acting as oncogenes or tumor suppres-
sors [4,18]. In the current study, by using high-throughput
microarrays, we found that AFAP1-AS1 is markedly
upregulated in PDAC cell lines and in primary material,
and its overexpression correlates with lymph node metas-
tasis, perineural invasion, and poor prognosis of PDACpatients. These observations suggest pro-oncogenic activ-
ity of AFAP1-AS1, a notion that is further supported by
our functional studies showing that AFAP1-AS1 knock-
down attenuates PDAC cell proliferation, migration, and
invasion.
Lymph node metastasis and perineural invasion are
the strongest indicators of short overall survival in
PDAC patients. Efforts have recently been made to iden-
tify molecular predictive factors in pancreatic cancer
patients [19-21]. In the current study, we observed that
AFAP1-AS1 overexpression is associated with lymph
node metastasis, perineural invasion, and overall survival
after surgical treatment, raising the possibility that this
lncRNA may provide a means of identifying high-risk
patients for more intensive therapy. Importantly, ROC
curve analysis revealed that AFAP1-AS1 has great poten-
tial in predicting tumor progression after surgery. In the
data set of our present study, we observed that an over
8-fold increase in AFAP1-AS1 expression in PDAC
tissues compared with adjacent non-tumor tissues was
associated with an extremely high risk of short-term
recurrence. Whether AFAP1-AS1 alone, or in combin-
ation with other markers, could predict PDAC short-
term recurrence required further research through
well-designed studies with larger sample size.
In this study, the clinical value of AFAP1-AS1 in PDAC
was supported by functional analysis, which showed that
AFAP1-AS1 suppression diminished migration, invasion,
and expression of EMT-related genes in PDAC cells, and
AFAP1-AS1 ectopic expression promoted these malignant
behaviors vice versa. This long noncoding RNA was first
reported by Wu et al. [22], who showed that AFAP1-AS1
is overexpressed in primary esophageal adenocarcinoma
tissues and regulates esophageal adenocarcinoma cell pro-
liferation, migration, and invasion. Consistent with the lat-
ter report, the findings of our study support a similar
oncogenic role for AFAP1-AS1 in PDAC. Importantly, our
data showed that AFAP1-AS1 was one of the most
intensely and frequently overexpressed lncRNA in PDAC,
further highlighting this transcript to be of significant
biological interest in the study of pancreatic cancer
pathogenesis.
The AFAP1-AS1 is derived from the antisense strand
of the AFAP1 (Actin Filament Associated Protein) gene,
the sense strand of which encodes the protein AFAP1.
Figure 5 Ectopic expression of AFAP1-AS1 promoted proliferation, migration, and invasion of pancreatic cancer cell. (a) AFAP1-AS1 expression
level was confirmed by qPCR 48 hours after transfection. (b) The effect of AFAP1-AS1 overexpression on PANC-1 cell proliferation was determined
by MTT assays. (c) Representative images of transwell assay after AFAP1-AS1 ectopic expression n in PANC-1 cells. (d) Analysis of OD (570 nm)
absorbance of crystal violet-stained cells in migration assay and invasion assay. (e) Relative mRNA expression levels of EMT-related genes
(normalized to β-actin) in PDAC cells after AFAP1-AS1 knockdown were determined by RT-qPCR. (f) Western blot analysis of E-cadherin, N-cadherin,
Vimentin, Slug, and Snial1. Data are represented as the mean ± s.d. from three independent experiments. Vector control denotes cells transfected with
empty vector. ***: P < 0.01, Student’s t-test.
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Figure 6 Inhibition of AFAP1-AS1 impaired pancreatic cancer cell tumorigenicity in vivo. (a) (b) Nude mice were subcutaneously injected into
the right axilla with 3 × 106 cells infected with shControl lentiviral vector (containing scrambled control shRNA) or shAFAP1-AS1 lentiviral
vector (containing shRNA targeting AFAP1-AS1). Tumor growth was then monitored using calipers, and the mice were killed two weeks after
injection. (c) The tumors were weighed, and compared between the groups. ***: P < 0.01, Student’s t-test.
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been investigated in both breast and prostate cancer. It
has been reported that AFAP1 regulates Src activity and
promotes the formation of actin stress fibers and focal
adhesions in breast cancer cells [23]. The loss of AFAP1
in prostate cancer cells reduced cell proliferation and
tumorigenesis in nude mice [24]. Usually, the antisense
RNA regulates expression of its cognate sense gene, but
Wu et al. demonstrated that AFAP1-AS1 had limited ef-
fect on AFAP1 expression, instead functioning in an al-
most AFAP1-independent manner [22]. Therefore, it will
be of great interest in future to investigate whether
AFAP1-AS1 is involved in regulating AFAP1. Whether
overexpression of AFAP1-AS1 is induced by hypomethy-
lation or other epigenetic mechanism also deserves fur-
ther study.Conclusions
In summary, we have identified that a long noncoding
RNA, AFAP1-AS1, is up-regulated in PDAC tissues and
serves as a negative prognostic factor for lymph node
metastasis, perineural invasion, and poor survival in
PDAC patients. The value of AFAP1-AS1 as a potential
prognostic biomarker and/or therapeutic target in PDAC
was supported by findings that knockdown of AFAP1-
AS1 in PDAC cells inhibits cell proliferation, motility,
and invasiveness in vitro.Additional files
Additional file 1: The primers used for the qRT-PCR analysis.
Additional file 2: Differentially expressed lncRNAs between PDAC
tissues and CP tissues.
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